Neoadjuvant osimertinib was evaluated in a small phase 2 study of 27 patients with stages I to IIIA EGFR-mutant NSCLC, showing 15% MPR, 48% partial response, and 44% lymph node downstaging [50]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.